Fushine’s FuNext Mycoprotein has officially passed the scientific evaluation process conducted under the U.S. FDA’s GRAS framework and received approval from an independent expert panel. This milestone positions Fushine among the very few Chinese companies in the synthetic biology field to gain recognized access to the U.S. market.

Technology-Driven Innovation and Independent R&D

FuNext Mycoprotein is produced from a next-generation filamentous fungi called Fusarium venenatum through precision fermentation. It offers a well-balanced nutritional profile rich in protein and key micronutrients, and is naturally low in sugar, fat, and cholesterol while providing beneficial dietary fiber. Its mild flavor and versatile functionality make it suitable for a wide range of food applications — including meat alternatives, protein beverages, baked snacks, nutritional supplements, plant-based dairy, and even pet nutrition. This flexibility highlights both its functional value and its potential for long-term market growth.

Global Certifications Demonstrate Safety and Quality

Over the past year, Fushine successfully transformed its microbial protein research into full-scale production and obtained major international food safety certifications, including ISO 22000, BRC, SQF, HACCP, and HALAL.

The new GRAS certification further validates the safety of FuNext Mycoprotein and grants it formal market access in the United States, as well as in other regions that recognize GRAS approval. This advancement will accelerate the expansion of Fushine’s microbial protein business, strengthen its global presence, and contribute positively to the company’s long-term development.

Advancing Industrialization With Multiple Product Formats

FuNext Mycoprotein comes in two forms—dry and wet—giving it strong compatibility across downstream food categories. The company has already completed a dedicated 1,200-ton production line, which is operating steadily, and construction of the Phase I 200,000-ton mycoprotein and resource-utilization project is currently underway.

A Milestone for New-Quality Productivity

From R&D breakthroughs to industrial-scale deployment, FuNext Mycoprotein has become an excellent example of Fushine’s commitment to new-quality productivity. The company will continue to contribute to meeting the public’s growing demand for diverse, high-quality, and nutritious protein solutions.

FuNext Mycoprotein Wet (Left) and Dry (Right) Forms

FuNext Mycoprotein: Expanding Applications Across Consumer Products

Looking Ahead: Unlimited Potential

With the rapid global growth of the synthetic biology industry and increasing consumer demand for healthier diets, FuNext Mycoprotein is well-positioned to shine in the future marketplace. Its successful U.S. GRAS certification marks a significant milestone, opening broader international opportunities and strengthening confidence in its safety and quality.

Fushine will continue to deepen its investment in research and development, further optimizing the production technology and quality of FuNext Mycoprotein while expanding its applications across a wider range of food categories. By doing so, the company aims to support innovation within the global food industry and contribute to a healthier, more sustainable future.